Vicente-Hernández B, Sarre-Álvarez D, Rodríguez-Weber FL, Díaz-Greene EJ

Language: Spanish
References: 22
Page: 567-577
PDF size: 470.50 Kb.

ABSTRACT

The anthracyclines have been the cornerstone of various chemotherapeutic schemes for hematological malignancies and solid tumors however the cardiotoxicity produced is a limitation for use. Damage mechanisms ranging from inhibition of DNA replication, RNA transcription, generating free radicals which damage DNA and lipid peroxidation inhibition of topoisomerases. The cumulative dose is one of the major risk factors, among others such as age, presence of other cardiovascular diseases and concomitant use of other agents. Because the prognosis of patients, have sought diagnostics and prediction of cardiotoxicity such as biomarkers like a troponin I and BNP; and imaging studies such as echocardiography, MRI and nuclear medicine. Another point of interest in the issue are the preventive measures, as has been the use of pegylated forms, the use of dexrazoxane and use of ACE inhibitors and beta blockers, each one targeting to different pathophysiological mechanism. Efforts are directed to the nearby monitoring of patients with non-invasive imaging studies for early detection of patients, to establish those unable to continue therapy for high risk of developing left ventricular dysfunction.

REFERENCES

1. Volkova M, Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011(7):214-220.

2. Sawyer D, Peng X, Pentassuglia L, et al. Mechanism of anthracycline cardiac injury: Can we identify strategies for cardioprotection? Prog Cardiovasc Dis 2010;53(2):105-113.

3. Plana J. La quimioterapia y el corazón. Rev Esp Cardiol 2011; 64(5):409-415.

4. Nakamae H, Tsumura K, Terada Y. Notable Effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorrubicin, vincristine and prednisolone. Am Cancer Soc 2005(104)11:2492-2498.

5. Smith L, Cornelius V, Plummer C, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomized controlled trials. BMC Cancer 2010;10: 337.

6. Dolci A, Dominici R, Cardinale D, et al. Biochemical markers for prediction of chemotherapy-Induced cardiotoxicity. Systematic Review of the literature and recommendations for use. Am J Clin Pathol 2008;130:688-695.

7. Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicintreated lymphoma patients: A prospective, parallel-group, randomized, controlled study with-36 month follow-up. Am J Hematol 2010:85(11):894-896.

8. Wojnowski L, Kulle B., Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-3762.

9. McCaffrey T, Tziros C, Lewis J, et al. Genomic Profiling reveals the potential role of TCL IA and MDR 1 Deficiency in chemotherapy- Induced cardiotoxicity. Int J Biol Sci 2013;9(4):350-360.

10. Sawyer D. Anthracyclines and heart failure. N Engl J Med. 2013; 368(12):1154-1156.

11. Zhang Y, Shi J, Li Y, et al. Cardiomyocyte death in doxorrubicin-induced cardiotoxicity. Arch Immunol Ther Exp 2009;57(6):435-445.

12. Sandri M, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005;51:1405-1410.

13. Saidi A, Alharethi R. Management of chemotherapy induced cardiomyopathy. Current Cardiolo Rev 2011;7(4):245-249.

14. Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000;104:158-163.

15. Pichon M, Cvitkovic F, Hacene K, et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In vivo 2005;19:567-576.

16. Sawaya H, Sebag I, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy- treated patients. Am J Cardiol 2011;107:1375-1380.

17. Jiji R, Kramer C, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol 2012;19(2):377-388.

18. Sawaya H, Sebag I, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with antracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596-603.

19. De Geous-Oeq L, Mavinkurve-Groothuis A, Bellersen L, et al. Scintigrafic techniques for early detection of cancer treatmentinduced cardiotoxicity. J Nucl Med 2011;52:560-571.

20. Xi L, Zhu S, Das A, et al. Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications. Nitric Oxide 2012;26(4):274-284.

21. Scott J, Khakoo A, Mackey J, et al. Modulation of anthracycline- induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation 2011;124(5):642-650.

22. Jensen B, Nielsen S, Skovsgaard T. Treatment with angiotensina-converting-enzime inhibitor for epirrubicin- induced dilated cardiomyopathy. Lancet 1996;347(8997):297-299.